Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232

Eric C. Larsen, MD, Wanda Salzer, MD, James Nachman, MD, Meenakshi Devidas, PhD, David R. Freyer, DO, MS, Elizabeth A. Raetz, MD, Naomi Winick, MD, Stephen P. Hunger, MD, William L. Carroll, MD

Blood (2011) 118 (21): 1510.

https://doi.org/10.1182/blood.V118.21.1510.1510

Published: 2011

Journal Articles

Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232

Michael J. Borowitz, MD, PhD, Brent L. Wood, MD, PhD, Meenakshi Devidas, PhD, Mignon L Loh, MD, Elizabeth A. Raetz, MD, Wanda Salzer, MD, James Nachman, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Julie M. Gastier-Foster, PhD, Cheryl L Willman, MD, Stephen B. Linda, MS, Naomi Winick, MD, Stephen Hunger, MD, William L. Carroll, MD, Eric C. Larsen, MD

Blood (2011) 118 (21): 1440.

https://doi.org/10.1182/blood.V118.21.1440.1440

Published: 2011

Journal Articles

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

Frank G Keller, MD, James Nachman, MD, Louis Constine, MD, John Thomson, MD, Kathleen M McCarten, MD, Lu Chen, PhD, Cindy Schwartz, MD

Blood (2010) 116 (21): 767.

https://doi.org/10.1182/blood.V116.21.767.767

Published: 2010

Journal Articles

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen Hunger, MD, Anne Angiolillo, MD, Meenakshi Devidas, PhD, Mei La, Nyla A. Heerema, Ph.D., Naomi Winick, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Paul S Gaynon, MD

Blood (2010) 116 (21): 497.

https://doi.org/10.1182/blood.V116.21.497.497

Published: 2010

Journal Articles

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Yousif Matloub, MD, Anne Angiolillo, MD, Bruce Bostrom, MD, Stephen P. Hunger, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Naomi Winick, MD, Paul S. Gaynon, MD

Blood (2006) 108 (11): 146.

https://doi.org/10.1182/blood.V108.11.146.146

Published: 2006

Journal Articles

Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (>200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group.

Caroline Hastings, MD, Harland N. Sather, PhD, Nita L. Seibel, MD, James Nachman, MD, Peter G. Steinherz, MD, Kathy Bertolone, FNP, Cynthia DeLaat, MD, Lawrence J. Ettinger, MD, Janet Franklin, MD, David Robert Freyer, DO, Leonard A. Mattano, MD, Torrey L. Mitchell, MD, Charles M. Rubin, MD, Allan F. Pyesmany, MD, Nyla A. Heerema, PhD, Cheryl Edens, Paul S. Gaynon, MD

Blood (2006) 108 (11): 1870.

https://doi.org/10.1182/blood.V108.11.1870.1870

Published: 2006

Journal Articles

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Yousif Matloub, MD, B.L. Asselin, Linda C. Stork, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, James Nachman, MD, Bruce Camitta, MD, Paul S. Gaynon, MD

Blood (2004) 104 (11): 680.

https://doi.org/10.1182/blood.V104.11.680.680

Published: 2004

NARROW

TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232

Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (>200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group.

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Email alerts

ASH Publications

American Society of Hematology

TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232

Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (>200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group.

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only